After 6 months, placebo was associated with a mean weight gain of 0.4 kg (o.88 lb), compared with 1.2-1.9 kg (2.6-4.2 lb) ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Income investors have liked Pfizer (NYSE: PFE) for years. However, the big drugmaker's exceptionally juicy dividend these ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, “which we are unable to predict at this time.” ...

There are significant questions on how the order can be implemented, and if companies can raise prices on already approved ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Pfizer's robust product pipeline and consistent R&D investments position it well for future growth. See why I rate PFE stock a strong buy ahead of earnings.

With its stock down 7.6% over the past three months, it is easy to disregard Pfizer (NYSE:PFE). We, however decided ...